The bioavailability of digoxin from three oral formulations measured by a specific h.p.l.c. assay
about
Digoxin-specific antibody fragments in the treatment of digoxin toxicity.Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).ABCB1 and SLCO1B3 Gene Polymorphisms and Their Impact on Digoxin Pharmacokinetics in Atrial Fibrillation Patients among the Tunisian Population.The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects.
P2860
The bioavailability of digoxin from three oral formulations measured by a specific h.p.l.c. assay
description
1993 nî lūn-bûn
@nan
1993 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
The bioavailability of digoxin ...... d by a specific h.p.l.c. assay
@ast
The bioavailability of digoxin ...... d by a specific h.p.l.c. assay
@en
The bioavailability of digoxin ...... d by a specific h.p.l.c. assay
@nl
type
label
The bioavailability of digoxin ...... d by a specific h.p.l.c. assay
@ast
The bioavailability of digoxin ...... d by a specific h.p.l.c. assay
@en
The bioavailability of digoxin ...... d by a specific h.p.l.c. assay
@nl
prefLabel
The bioavailability of digoxin ...... d by a specific h.p.l.c. assay
@ast
The bioavailability of digoxin ...... d by a specific h.p.l.c. assay
@en
The bioavailability of digoxin ...... d by a specific h.p.l.c. assay
@nl
P2093
P2860
P1476
The bioavailability of digoxin ...... d by a specific h.p.l.c. assay
@en
P2093
A Van Vliet-Verbeek
D D Breimer
H C Brandenburg
P2860
P304
P356
10.1111/J.1365-2125.1993.TB05679.X
P407
P577
1993-02-01T00:00:00Z